These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 19364815)

  • 1. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.
    Pedersen K; Angelini PD; Laos S; Bach-Faig A; Cunningham MP; Ferrer-Ramón C; Luque-García A; García-Castillo J; Parra-Palau JL; Scaltriti M; Ramón y Cajal S; Baselga J; Arribas J
    Mol Cell Biol; 2009 Jun; 29(12):3319-31. PubMed ID: 19364815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p95HER2 and breast cancer.
    Arribas J; Baselga J; Pedersen K; Parra-Palau JL
    Cancer Res; 2011 Mar; 71(5):1515-9. PubMed ID: 21343397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation.
    García-Castillo J; Pedersen K; Angelini PD; Bech-Serra JJ; Colomé N; Cunningham MP; Parra-Palau JL; Canals F; Baselga J; Arribas J
    J Biol Chem; 2009 Sep; 284(37):25302-13. PubMed ID: 19589785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
    Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
    Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic characterization of Her2/neu-overexpressing breast cancer cells.
    Chen H; Pimienta G; Gu Y; Sun X; Hu J; Kim MS; Chaerkady R; Gucek M; Cole RN; Sukumar S; Pandey A
    Proteomics; 2010 Nov; 10(21):3800-10. PubMed ID: 20960451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of heregulin by mouse mammary tumor cells: role in activation of ErbB receptors.
    Schmitt M; Walker MP; Richards RG; Bocchinfuso WP; Fukuda T; Medina D; Kittrell FS; Korach KS; DiAugustine RP
    Mol Carcinog; 2006 Jul; 45(7):490-505. PubMed ID: 16482517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors.
    Chan R; Muller WJ; Siegel PM
    Ann N Y Acad Sci; 1999; 889():45-51. PubMed ID: 10668481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis.
    Worzfeld T; Swiercz JM; Looso M; Straub BK; Sivaraj KK; Offermanns S
    J Clin Invest; 2012 Apr; 122(4):1296-305. PubMed ID: 22378040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.
    Korkaya H; Paulson A; Iovino F; Wicha MS
    Oncogene; 2008 Oct; 27(47):6120-30. PubMed ID: 18591932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
    Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
    Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.
    Siegel PM; Ryan ED; Cardiff RD; Muller WJ
    EMBO J; 1999 Apr; 18(8):2149-64. PubMed ID: 10205169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
    Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
    Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
    Jacquemart IC; Springs AE; Chen WY
    Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.